Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

VKTX is trading 23% below the $35 price of its own secondary offering, a rare inversion that follows a $575 million raise to fund phase 3 development of VK2735, its weight loss candidate.

The post-offering slide reflects dilution concerns, per the source. Investors who bought into the raise at $35 are sitting on sizable paper losses, while the capital itself is now locked in for late-stage work.

VK2735 is a dual GLP-1/GIP receptor agonist. Viking is advancing it in both injectable and oral formats, giving the company two shots at a market projected to reach nearly $100 billion by decade's end. That market is already shaped by LLY and NVO, the incumbents against which any VKTX data will be measured.

Interpretation: a stock trading well below its fresh offering price suggests the market is pricing the dilution now while assigning little premium to phase 3 execution. The Motley Fool piece argues this setup favors patient buyers. That is a thesis, not a certainty, since phase 3 outcomes remain unproven.